11 results about "FtsZ" patented technology

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The invention belongs to the field of new drug compounds, and particularly relates to a heterocyclic ethylene-substituted pyridine quaternary ammonium salt dual-mechanism antibacterial agent as well as a preparation method and application thereof. The heterocyclic ethylene-substituted pyridine quaternary ammonium salt derivative is completely different from a reported dual-mechanism antibacterial agent capable of targeting bacteria FtsZ and cell membranes in structure and has different physicochemical properties, and experiments show that the derivative has an effect of inhibiting the FtsZ, can be used as a novel FtsZ inhibitor, and can be used for splitting the bacterial cell membranes and inhibiting the bacterial cell membranes. The antibacterial activity is good.

The application discloses a non-coding sRNA for regulating gene expression and application thereof, and belongs to the technical field of biology. The application firstly finds that the non-coding sRNA formed by the combination of any one of the transcription terminator (or endogenous terminator) independent of the rho factor and a specific mRNA complementary pairing region of a target gene can play a gene regulation function. The discovery is taken as a basic and universal principle to design the non-coding sRNA, so that the purpose of specifically regulating the expression of any gene can be achieved. Taking the gfp, ftsZ gene and the synthesis bypass pathway of the ergothioneine synthesis substrate as examples, it is verified that the non-coding sRNA designed under the design principle can effectively regulate the expression of the gfp and ftsZ, or improve the ergothioneine yield. The method of the application can provide more effective and convenient regulation technology for the gene regulation of prokaryotes, and can realize the rapid regulation of any gene.

The invention discloses a quaternary ammonium salt derivative as well as a preparation method and application thereof. The structural general formula of the quaternary ammonium salt derivative is shown as a formula I or a formula II. The quaternary ammonium salt derivative disclosed by the invention plays a role in inhibiting bacteria type I signal peptidase (SPase I) and temperature-sensitive mitoprotein Z (FtsZ), and plays a key role in survival and toxicity of bacteria.

The application discloses a kind of Bacillus subtilis small RNA regulatory system construction method, belong to the field of bioengineering technology.The present application can quickly design to produce a large number of sRNA regulatory tools to knock down the gene expression in Bacillus subtilis.Compared with other regulation methods, the present application does not need to express other RNA chaperone proteins and other genes, and does not need to modify the target gene, and is simple and efficient in operation.Secondly, the present application can quickly design a large number of artificial sRNA regulatory tools with different sequences, which enriches the types and quantities of the regulation element library.Using the sRNA of the present application can achieve different degrees of inhibition of Bacillus subtilis exogenous genes gfp, endogenous genes ftsZ, comER, aslR, aslD, ldh, pta, acoA, bdhA, etc., which can effectively regulate the expression of the target gene.

The present invention belongs to the fields of genetic engineering and microbial technology, and specifically relates to the use of split genes in regulating threonine synthesis, cell morphology, and growth. Experiments have demonstrated that regulating the expression intensity of split genes through biological elements can affect threonine synthesis, cell morphology, and growth of target microorganisms. For example, when ftsZ expression is too strong, it has little effect on microbial cell growth and threonine production, and may even be detrimental to threonine production. However, when ftsZ expression is relatively weak, it is beneficial to the accumulation of cell biomass and promotes threonine synthesis. Therefore, by regulating the expression intensity of the split genes, dynamic regulation of threonine production by bacterial strain fermentation is achieved, which is not only beneficial for actual production but also can be used as a model strain for research on the mechanism of threonine synthesis, cell morphology, and growth, thus having excellent practical application value.

The present invention provides an application of a cell division protein FtsZ targeted inhibitor in the preparation of an anti-drug resistant bacteria drug, belonging to the technical field of drug research and development. The inhibitor provided by the present invention is compound A3, named (1-methyl-2-((Z)-(3-methylbenzo[d]thiazole-2(3H)-ylidene)methyl)-4-((E)-4-(4-methylpiperazine-1-yl)styryl)quinoline-1-iodide, with a molecular formula of C 32 H 33 IN4S. The compound A3 has a significant inhibitory effect on multiple drug-resistant bacteria, especially vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, and can significantly increase the sensitivity of methicillin to methicillin-resistant Staphylococcus aureus.

The application belongs to the technical field of microorganism detection, and particularly relates to a detection nucleotide sequence of a Chinese mitten crab spiroplasma and application thereof. The application designs a fluorescence quantitative PCR detection primer and probe based on a probe method for the ftsZ gene of the Chinese mitten crab spiroplasma. The detection sensitivity of the target gene in the detection is 3.3 copies / reaction, and the method has the advantages of specificity, rapidness and stable results, and is suitable for early monitoring and epidemiological investigation of river crab spiroplasma disease.

The invention belongs to the technical field of biology, and particularly relates to a hybrid peptide targeting bacteria FtsZ and cell membranes as well as a preparation method and application of the hybrid peptide. The amino acid sequence of the hybrid peptide is as shown in SEQ ID NO. 1-21. According to the hybrid peptide, SulA (88-106), A3 and B1 designed and synthesized by a research group are used as mother peptides, and 21 hybrid peptides are designed and synthesized based on four modification strategies of fatty acid connection, cyclization, dimerization and cell-penetrating peptide connection. The hybrid peptide provided by the invention shows more excellent broad-spectrum antibacterial activity, the FtsZ protein and cell membrane double-target effect is strongest, the toxicity is low, and the in-vivo pharmacodynamic effect is good. The hybrid peptide provided by the invention provides a new thought for solving the drug resistance problem, and provides a candidate drug for the development of novel double-target antibacterial peptides.

The invention discloses application of a bacterial division protein FtsZ inhibitor DB1 in preparation of drugs for resisting drug-resistant bacteria, and belongs to the technical field of drug research and development. The inhibitor provided by the invention is a compound DB1, the name of the compound DB1 is 3-(2, 8-dibromo-10, 11-dihydro-5H-dibenzo [b, f] azepine-5-yl)-N, N-dimethyl propylamine hydrochloride, and the molecular formula of the compound DB1 is C19H24Br2ClN2. The compound DB1 has a remarkable inhibition effect on various drug-resistant bacteria, particularly has a very strong inhibition effect on vancomycin-resistant enterococcus and methicillin-resistant staphylococcus aureus, and can be used for remarkably improving the sensitivity of methicillin to the methicillin-resistant staphylococcus aureus. The discovery of the compound DB1 provides a new thought and technical support for preparation of drugs for resisting drug-resistant bacteria.